Akebia Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Akebia reported Q3 '26 total revenues of $36.9 million, compared with $58.8 million in Q3 '25.
- Vafseo net product revenues were $14.8 million, compared with $14.3 million in Q3 '25, while Eryxia net product revenues were $20 million, compared with $42.5 million.
- The company reported a net loss of $14.4 million in Q3 '26, versus net income of $0.5 million in Q3 '25.
- Research and development expenses were $16.2 million, selling, general and administrative expenses were $23.5 million, and cost of goods sold was $6.4 million in Q3 '26.
- Akebia ended the quarter with $159.3 million in cash and cash equivalents, including $6.6 million in ATM proceeds raised early in the quarter.
- Vafseo had about 11,500 patients on therapy last quarter, representing about 20% of patients treated for anemia at USRC, DCI, and IRC; 25% of patients who had discontinued therapy had restarted.
- Management said estimated end-user demand was between $19 and $20 million in Q3, while reported Vafseo net product revenues were $14.8 million, primarily because customers reduced inventory based on lower average doses and dialysis compliance.
- The VOICE trial enrolled 2,116 patients and met its predefined stopping criteria, with win odds of 1.16 and a p-value of 0.0016; it established non-inferiority and superiority on the primary composite endpoint due to fewer hospitalizations.
- VOICE showed hospitalizations were 10% lower with vatadustat than with ESA, without a significant difference in mortality rates, and exposure-adjusted serious adverse events were lower with vatadustat.
- Akebia announced positive top-line results from the VOICE-CL study, which showed vatadustat dosed TIW was non-inferior to ESA in maintaining hemoglobin.
- Akebia’s Phase 2 trials of pralisoquat in FSGS and abribifus in a basket trial in C3G, IgAN, and lupus nephritis are enrolling.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to Akebia's third quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your first speaker today, Mercedes Carrasco, Senior Director, IR.
You may begin. Thank you, and welcome to Akebia's third quarter 2026 financial results and business updates conference call.
Please note that a press release was issued earlier today, Thursday, November 5, detailing our third quarter 2026 financial results, and that release is available on the investor section of our website. For your convenience, a replay of today's call will also be available on our website after we conclude. Joining me for today's call, we have John Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer. Dr. Steven Burke, our Chief Medical Officer, and Nicholas Grund, Chief Commercial Officer, are also available for questions. I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements.
Additional information describing these risks is included in the financial results press release that we issued on November 5, as well as in the risks, factors, and management discussion and analysis section of our most recent annual and quarterly reports filed with the SEC. With that, I'd like to introduce our CEO, John Butler.
Thanks, Mercedes. Good morning, everyone, and thank you for joining us today. Late last month, Akebia joined our peers at ASN Kidney Week in Denver. I left the event with two important takeaways. First, I heard tremendous excitement about the VOICE trial data that Dr. Block of USRC presented. We believe the data, which demonstrated a clear and compelling hospitalization outcomes benefit for vadadustat versus an ESA, dose in a regimen that most dialysis providers have chosen to implement, will have dialysis organizations thinking differently about Vafseo, and over time, has the potential to drive Vafseo to become standard of care. Second, the spotlight continues to shine on rare kidney disease therapeutic product development, and we're excited about the potential to show meaningful differentiation with our mid-stage pipeline assets across multiple rare kidney indications. We believe this would represent significant value for our shareholders.
Now, with this backdrop, let me walk through Q3, starting with our commercial business. We are pleased with the pace at which we are adding patients from the mid-sized dialysis providers, including USRC, DCI, and IRC. Last quarter, the number of patients on Vafseo increased to about 11,500 patients on therapy, representing about 20% of patients treated for anemia within these three dialysis organizations. Also important, 25% of patients that had previously discontinued therapy have restarted. Even with this progress, I believe we have significant room to continue driving growth even within the mid-sized dialysis providers, but obviously and especially at the large dialysis organizations. Vafseo net product revenues were $14.8 million for the quarter. This is only a 3% increase versus the third quarter of last year, despite approximately 140% growth in the number of patients on therapy.
There are a few somewhat related factors at play, but it was predominantly a drawdown of inventory based on a lower dose and dialysis compliance rate. If you recall, we told you that we are no longer getting data on average dose at providers who have moved to TIW dosing. When our largest customer looked at their utilization, they adjusted their purchases based on the average dose they were seeing versus what they expected. Our customer made their inventory assumptions expecting an average dose of 900 milligrams per dialysis treatment, but the average was about 810 milligrams. Even more impactful, patients have been less compliant with their dialysis sessions than expected. If a patient doesn't show up for dialysis, the patient doesn't receive a Vafseo dose if the unit is using observed dosing.
These two factors combined meant that there was more inventory in their clinics at the end of last quarter, which impacted their purchases this quarter. So to make it very clear, when we use the updated dose and compliance data with the number of patients on therapy, end-user demand was between $17 million and $18 million for Q2 and between $19 million and $20 million for Q3. Another takeaway from my conversations at ASN is that while dialysis providers have protocols in place, as individual physicians start using Vafseo in greater numbers, they are using their own strategies to utilize the product and bring patients into or keep patients in the hemoglobin target range. This shouldn't be surprising. It took 20 years for physicians to figure out how to dose ESAs.
It is gratifying to see prescribers recognize the benefits of Vafseo for their patients, though it would be easier for us if their approaches were a little more consistent. Our focus is to continue to drive more patients onto therapy and support physicians as they look for the best outcomes for their patients. Beyond the reduction in inventory based on dose and dialysis compliance, as we approach Vafseo's January 1, 2027 TDAPA expiration, we expect a continued reduction in inventory levels. No provider wants drug on the shelf that it bought at a higher price when it no longer gets to bill for that price. Now, we are working proactively to manage this dynamic. To be clear, for Q4, we expect to see continued growth in patients on therapy. That is the most important metric for the long-term growth of the product. On January 1, we begin our post-TDAPA launch.
On that day, Vafseo access will expand beyond the TDAPA-only patients to nearly all clinically eligible patients. Treatment with Vafseo will be reimbursed as part of the dialysis bundle payment, and dialysis organizations will no longer be able to bill separately when they use the product. As we've always said, post-TDAPA will price Vafseo to remain competitive with ESA pricing to ensure providers can access an innovative treatment for patients, even within the economic confines of a bundled payment system. What does this mean for pricing in 2027 and beyond? While we're still working on some of our post-TDAPA contracts, we know ESA price has decreased over time, and now incorporating a somewhat lower dose and dialysis compliance, we expect the average annual cost of therapy to fall somewhere between $1,000 and $1,500.
Certainly not the price you would normally expect for a product bringing the level of innovation that Vafseo brings, but these are the dynamics of the dialysis market. If we can make Vafseo standard of care, which means ultimately treating at least 200,000 to 250,000 patients, that would mean a potential multi-hundred million dollar peak revenue. How are we going to get there? As I said, in Q4, even though we expect our customers to be conservative with inventory, we expect to continue to see an increase in patients. We expect Q4 patient growth will be driven primarily by our current mid-sized dialysis providers, USRC, IRC, and DCI. We share our shareholders' desire to see DaVita and Fresenius begin contributing to our revenue.
While we have a post-TDAPA contract with DaVita for 2027, at their request, we're working on a multi-year extension of that contract, and they've outlined their plans to begin rolling out the product slowly, which we expect to start this quarter, and in a much more significant way early next year. It's clearly been frustrating for us that adoption among the large dialysis providers has not progressed more quickly. But in the end, it's clinical evidence that changes the way prescribers think about patient care. Let me give you a few highlights from the VOICE data presented by Dr. Block at ASN. The trial enrolled 2,116 patients and met the predefined stopping criteria with a win odds of 1.16 and a P-value of 0.0016, establishing non-inferiority and superiority of the primary composite endpoint due to reduction in hospitalizations.
The data demonstrated that hospitalizations were 10% lower in patients treated with vadadustat versus ESA, without a significant difference in mortality rates. Exposure-adjusted serious adverse events were lower with vadadustat, with 121.5 events per 100 patient-years compared to 134.2 events per 100 patient-years for patients treated with ESAs. Given that SAEs generally drive hospitalization, this is not a surprising finding. As we've seen in the past, vadadustat showed more stable hemoglobin control versus ESAs. In an exploratory endpoint, the data showed the odds of high hemoglobin excursions were reduced in patients treated with vadadustat compared to ESA, while there was no overall difference in low excursions. There has never been an outcome study performed before VOICE that compared treatments for patients with anemia due to CKD that demonstrated an outcomes difference.
Recall, like the VOICE primary endpoint, the post-hoc win statistics analysis of our INNO2VATE study also demonstrated a statistically significant lower risk of dying or being hospitalized for patients receiving vadadustat versus ESAs. The health economic analysis of the VOICE hospitalization benefit will be completed, but we presented an updated economic analysis from INNO2VATE at the ASN. This analysis suggested that treatment with Vafseo resulted in a $6,200 lower annual cost of hospitalization per patient compared with ESA. Based on the assumptions used in the analysis, if all eligible dialysis patients with anemia were treated with Vafseo, it could result in more than 600,000 fewer hospital days versus ESA treatment. We have seen and know that adoption in nephrology, particularly dialysis, moves slowly, but this is the data that gives me the confidence to believe that Vafseo will ultimately become standard of care.
This morning, we announced positive top-line results from the VOCAL study, which we conducted at DaVita clinics. One more study demonstrating vadadustat dose TIW is non-inferior to ESA in maintaining hemoglobin. We look forward to continuing the analysis of VOCAL to see what further differentiation we may be able to uncover. ASN was also a great meeting when considering our rare kidney disease pipeline. A significant part of the meeting agenda was dedicated to advances in treating rare kidney diseases. We presented preclinical data that informed our confidence in praliciguat for FSGS, as well as posters on our phase II trial designs for both ebribafusp and praliciguat. Additionally, Dr. Jim Tumlin presented to a full house in an exhibitor spotlight focusing on both prali and ebri. I was pleased with the interest in both programs from the interactions the team had with investigators and potential investigators.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
